PEOPLE: PatiEnt prOstate samPLes for rEsearch, a tissue collection pathway utilizing magnetic resonance imaging data to target tumor and benign tissue in fresh radical prostatectomy specimens.
biobank
cancer
magnetic resonance imaging
prostate
sampling
specimen
tissue
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
16
11
2018
accepted:
07
02
2019
pubmed:
27
2
2019
medline:
14
1
2020
entrez:
27
2
2019
Statut:
ppublish
Résumé
Over 1 million men are diagnosed with prostate cancer each year worldwide, with a wide range of research programs requiring access to patient tissue samples for development of improved diagnoses and treatments. A random sampling of prostate tissue is sufficient for certain research studies; however, there is growing research need to target areas of the aggressive tumor as fresh tissue. Here we set out to develop a new pathway "PEOPLE: PatiEnt prOstate samPLes for rEsearch" to collect high-quality fresh tissue for research use, using magnetic resonance imaging (MRI) to target areas of tumor and benign tissue. Prostate tissue was sampled following robotic radical prostatectomy, using MRI data to target areas of benign and tumor tissue. Initially, 25 cases were sampled using MRI information from clinical notes. A further 59 cases were sampled using an optimized method that included specific MRI measurements of tumor location along with additional exclusion criteria. All cases were reviewed in batches with detailed clinical and histopathological data recorded. For one subset of samples, DNA was extracted and underwent quality control. Ex vivo culture was carried out using the gelatin sponge method for an additional subset. Tumor was successfully fully or partially targeted in 64% of the initial cohort and 70% of the optimized cohort. DNA of high quality and concentration was isolated from 39 tumor samples, and ex vivo culture was successfully carried out in three cases with tissue morphology, proliferation, and apoptosis remaining comparable before and after 72 hours culture. Here we report initial data from the PEOPLE pathway; using a method for targeting areas of tumor within prostate samples using MRI. This method operates alongside the standard clinical pathway and minimizes additional input from surgical, radiological, and pathological teams, while preserving surgical margins and diagnostic tissue.
Sections du résumé
BACKGROUND
Over 1 million men are diagnosed with prostate cancer each year worldwide, with a wide range of research programs requiring access to patient tissue samples for development of improved diagnoses and treatments. A random sampling of prostate tissue is sufficient for certain research studies; however, there is growing research need to target areas of the aggressive tumor as fresh tissue. Here we set out to develop a new pathway "PEOPLE: PatiEnt prOstate samPLes for rEsearch" to collect high-quality fresh tissue for research use, using magnetic resonance imaging (MRI) to target areas of tumor and benign tissue.
METHODS
Prostate tissue was sampled following robotic radical prostatectomy, using MRI data to target areas of benign and tumor tissue. Initially, 25 cases were sampled using MRI information from clinical notes. A further 59 cases were sampled using an optimized method that included specific MRI measurements of tumor location along with additional exclusion criteria. All cases were reviewed in batches with detailed clinical and histopathological data recorded. For one subset of samples, DNA was extracted and underwent quality control. Ex vivo culture was carried out using the gelatin sponge method for an additional subset.
RESULTS
Tumor was successfully fully or partially targeted in 64% of the initial cohort and 70% of the optimized cohort. DNA of high quality and concentration was isolated from 39 tumor samples, and ex vivo culture was successfully carried out in three cases with tissue morphology, proliferation, and apoptosis remaining comparable before and after 72 hours culture.
CONCLUSION
Here we report initial data from the PEOPLE pathway; using a method for targeting areas of tumor within prostate samples using MRI. This method operates alongside the standard clinical pathway and minimizes additional input from surgical, radiological, and pathological teams, while preserving surgical margins and diagnostic tissue.
Identifiants
pubmed: 30807665
doi: 10.1002/pros.23782
pmc: PMC6618051
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
768-777Subventions
Organisme : Prostate Cancer UK
ID : PG14-018-TR2
Pays : United Kingdom
Organisme : Prostate Cancer UK
ID : Centre of Excellence
Pays : United Kingdom
Organisme : Department of Health
ID : Biomedical Research Centre
Pays : United Kingdom
Organisme : Prostate Cancer UK
ID : TLD-PF16-004
Pays : United Kingdom
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Prostate. 2019 May;79(7):768-777
pubmed: 30807665
Front Oncol. 2017 Mar 24;7:47
pubmed: 28393049
Lancet. 2017 Feb 25;389(10071):815-822
pubmed: 28110982
Br J Cancer. 2017 Apr 25;116(9):1159-1165
pubmed: 28350785
Front Oncol. 2018 Oct 02;8:400
pubmed: 30333957
Diagn Mol Pathol. 2012 Jun;21(2):61-8
pubmed: 22555088
Prostate. 2013 Jan;73(2):194-202
pubmed: 22806573
Nat Rev Urol. 2013 Aug;10(8):483-7
pubmed: 23752995
J Transl Med. 2017 Nov 7;15(1):229
pubmed: 29116016
Eur Urol. 2017 Aug;72(2):282-288
pubmed: 27574821
Prostate. 1994 Nov;25(5):274-9
pubmed: 7526353
Expert Rev Anticancer Ther. 2017 Dec;17(12):1159-1168
pubmed: 28933973
Prostate. 2017 Mar;77(4):396-405
pubmed: 27862105
J Transl Med. 2011 Jul 26;9:121
pubmed: 21791045
Int J Surg Pathol. 2009 Jun;17(3):238-43
pubmed: 18508841
BMC Cancer. 2016 Oct 21;16(1):816
pubmed: 27769214
J Clin Pathol. 2005 May;58(5):504-8
pubmed: 15858122